Table 1.
Existing MRI probe candidates with the ability to bind amyloid aggregates.
| Compound Names and Literature References | Target | Figure 1 |
|---|---|---|
| For 19F imaging | ||
| FSB [90] | Aβ | 8 |
| TFMB-2Et, TFMB-3Et [93] | Aβ | 9 |
| Shiga-Y5 [94,95] | Aβ | 10 |
| Shiga-X22 [67,96] | Aβ | 10 |
| Shiga-Y51 [97] | Soluble Aβ aggregates | 10 |
| 7d [98] | Aβ | 13 |
| BSA-capped GQDs functionalized with hydrofluorinated glucose [99] | Aβ | – |
| Shiga-X35 [49] | Tau | 26 |
| Lansoprazole [177] | Tau | 26 |
| For 1H contrast imaging, metal-based | ||
| Gd3+ chelates conjugated with Aβ binders [200,201,202,210,211,212,213,214] | Aβ | 29b |
| SPIONs conjugated with Aβ binders [203,204] | Aβ | – |
| ADx-001 [220,224] | Aβ | 31 |
1 The number of the figure showing the probe’s structure in the present paper.